Lung cancer

Junshi Biosciences Announces Acceptance by NMPA of Supplemental New Drug Application for Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Friday, July 30, 2021 - 1:40am

Esophageal squamous cell carcinoma and adenocarcinoma are the two main histological subtypes of esophageal cancer.

Key Points: 
  • Esophageal squamous cell carcinoma and adenocarcinoma are the two main histological subtypes of esophageal cancer.
  • Esophageal squamous cell carcinoma is the main subtype in China, accounting for 90% of all esophageal cancer.
  • For patients with advanced or metastatic esophageal squamous cell carcinoma, the current standard first-line treatment is platinum-based chemotherapy, but the 5-year overall survival rate is less than 20%.
  • In March 2021, toripalimab received Breakthrough Therapy Designation for the first-line treatment of advanced mucosal melanoma by the NMPA.

Pulmonx to Present at the Canaccord Genuity 41st Annual Growth Conference

Thursday, July 29, 2021 - 9:05pm

REDWOOD CITY, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021 at 8:30am PT / 11:30am ET.

Key Points: 
  • REDWOOD CITY, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021 at 8:30am PT / 11:30am ET.
  • Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease.
  • Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a breakthrough device.
  • Pulmonx, Chartis, StratX, and Zephyr are registered trademarks of Pulmonx Corporation.

GO2 Foundation for Lung Cancer to Honor Heather Wakelee, M.D. with the 2021 Bonnie J. Addario Lectureship Award

Friday, July 30, 2021 - 5:00pm

SAN CARLOS, Calif. and WASHINGTON, July 30, 2021 /PRNewswire/ -- GO2 Foundation for Lung Cancer (GO2 Foundation) will present Heather Wakelee, M.D.

Key Points: 
  • SAN CARLOS, Calif. and WASHINGTON, July 30, 2021 /PRNewswire/ -- GO2 Foundation for Lung Cancer (GO2 Foundation) will present Heather Wakelee, M.D.
  • with the 2021 Bonnie J. Addario Lectureship Award at thePhysicians' Education Resource 22nd Annual International Lung Cancer Congress on Friday, July 30 in Huntington Beach, California.
  • She has also collaborated with colleagues on work to better understand why lung cancer develops and better methods for detection of lung cancer.
  • "Given women are disproportionately impacted by lung cancer, the advancements in lung cancer research by women like Dr. Wakelee are incredibly meaningful to the lung cancer community.

American Lung Association on World Lung Cancer Day Announces New Patient Resources and Trends Brief

Thursday, July 29, 2021 - 4:32pm

CHICAGO, July 29, 2021 /PRNewswire/ --In recognition of World Lung Cancer Day, the American Lung Association announced new patient resources and a lung cancer trends brief to further advance support for lung cancer patients and caregivers.

Key Points: 
  • CHICAGO, July 29, 2021 /PRNewswire/ --In recognition of World Lung Cancer Day, the American Lung Association announced new patient resources and a lung cancer trends brief to further advance support for lung cancer patients and caregivers.
  • Lung Cancer Trends Brief: New this year, the Lung Association released this data on lung cancer mortality, incidence, prevalence and other key measures of the burden of this disease.
  • "World Lung Cancer Day presents a meaningful opportunity to highlight our new and existing lung cancer resources that offer support for those impacted by this devastating disease, while building additional awareness across the country," said American Lung Association National President and CEO Harold P. Wimmer.
  • The American Lung Association created LUNG FORCE, a national movement to defeat lung cancer, the leading cancer killer of women and men.

Oncocyte to Report Second Quarter 2021 Financial Results on Tuesday, August 10

Tuesday, July 27, 2021 - 3:35pm

The Company will host a conference call on Tuesday, August 10, 2021, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments.

Key Points: 
  • The Company will host a conference call on Tuesday, August 10, 2021, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments.
  • To access the live webcast, go to the investor relations section on the Companys website, or by clicking here: http://public.viavid.com/index.php?id=145975 .
  • The Companys tests are designed to help provide clarity and confidence to physicians and their patients at every stage of care.
  • DetermaRx identifies early-stage lung cancer patients who are at high risk for cancer recurrence and predicts benefit from adjuvant chemotherapy.

Community Healthcare System and Eon Partner to Help Detect Cancer in Its Earliest Stages

Monday, July 26, 2021 - 2:45pm

With Eon EPM, Community Healthcare System is ensuring these missed opportunities are captured and followed up on.

Key Points: 
  • With Eon EPM, Community Healthcare System is ensuring these missed opportunities are captured and followed up on.
  • "Finding breast and lung cancers at the earliest stages is the goal of every cancer program in the country," said Dr. Jonathon Lee, Medical Director of Cancer Services, Community Healthcare System.
  • For more information about cancer care services at the hospitals of Community Healthcare System, visit COMHS.org/cancer.
  • Community Healthcare System hospitals are regional leaders in cancer treatment, cardiac care, bariatric medicine and orthopedics.

Castle Biosciences Presents New Data Demonstrating DecisionDx®-SCC Complements Current Risk Assessment Methods in Patients with Cutaneous Squamous Cell Carcinoma of the Head and Neck

Friday, July 23, 2021 - 12:00pm

DecisionDx-SCC is Castles prognostic 40-gene expression profile (GEP) test for patients diagnosed with high-risk cutaneous squamous cell carcinoma (SCC), designed to use a patients tumor biology to predict individual risk of metastasis for patients with SCC and one or more risk factors.

Key Points: 
  • DecisionDx-SCC is Castles prognostic 40-gene expression profile (GEP) test for patients diagnosed with high-risk cutaneous squamous cell carcinoma (SCC), designed to use a patients tumor biology to predict individual risk of metastasis for patients with SCC and one or more risk factors.
  • The data further demonstrate that Castles DecisionDx-SCC test can provide clinicians with additional information on a patients metastatic risk to help them make more informed choices about their treatment and follow-up care.
  • All SCC tumor specimens were tested with DecisionDx-SCC and analyzed using Kaplan-Meier for metastasis-free survival (MFS) and Cox regression for risk of regional/distant metastasis.
  • DecisionDx-SCC is a 40-gene expression profile test that uses an individual patients tumor biology to predict individual risk of cutaneous squamous cell carcinoma metastasis for patients with one or more risk factors.

Ribon Therapeutics Announces Publication in Cancer Cell of Pre-Clinical and Mechanism of Action Data for RBN-2397

Thursday, July 22, 2021 - 6:00pm

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced the first publication in the peer-reviewed journal, Cancer Cell, of preclinical data from its lead asset, RBN-2397, a small molecule inhibitor of PARP7.

Key Points: 
  • Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced the first publication in the peer-reviewed journal, Cancer Cell, of preclinical data from its lead asset, RBN-2397, a small molecule inhibitor of PARP7.
  • PARP7 is overexpressed in a number of tumors, including squamous cell carcinoma of the lung (SCCL), which represents approximately 30% of all non-small cell lung cancers.
  • PARP7 is the first monoPARP to be targeted therapeutically and RBN-2397 is the first potent and selective PARP7 inhibitor to enter clinical development.
  • Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.

Pulmonx to Report Second Quarter 2021 Financial Results on August 3, 2021

Tuesday, July 20, 2021 - 9:05pm

REDWOOD CITY, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2021 after the close of trading on Tuesday, August 3, 2021. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Key Points: 
  • REDWOOD CITY, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (Pulmonx), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2021 after the close of trading on Tuesday, August 3, 2021.
  • Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT/4:30 p.m.
  • A live and archived webcast of the event will be available on the Investors section of the Pulmonx website at https://investors.pulmonx.com/ .
  • Pulmonx, Chartis, StratX, and Zephyr are registered trademarks of Pulmonx Corporation.

Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC)

Tuesday, July 20, 2021 - 5:34pm

Agilent Technologies Inc. (NYSE: A) today announced that the companys PD-L1 IHC 22C3 pharmDx assay is now labeled for expanded use in patients with non-small cell lung cancer (NSCLC) in the European Union.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced that the companys PD-L1 IHC 22C3 pharmDx assay is now labeled for expanded use in patients with non-small cell lung cancer (NSCLC) in the European Union.
  • PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying NSCLC patients with tumor PD-L1 expression of Tumor Proportion Score (TPS) 50% for treatment with Libtayo (cemiplimab).
  • This further demonstrates Agilents commitment to partnering with leading pharmaceutical companies to develop IHC-based diagnostics for targeted cancer therapy.
  • 4th LuCE report on lung cancer: Early diagnosis and screening challenges in lung cancer.